JPMorgan raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $517 from $515 and keeps an Overweight rating on the shares. The firm adjusted the company’s model ahead of the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals presents long-term data on CASGEVY
- Vertex Pharmaceuticals announces EC approval for Alyftrek for CF treatment
- Cautious Hold Rating for Vertex Pharmaceuticals Amid Limited Uptake and Insurance Challenges for Journavx
- Cautious Hold Rating on Vertex Pharmaceuticals Amid Promising Diabetes Treatment and Market Uncertainties
- Hold Rating on Vertex Pharmaceuticals: Balancing Promising Efficacy with Scalability and Commercial Viability Concerns for Zimislecel Therapy